glp-1 advertising policy news LegitScript's Data Reveals 1200% Increase in Violative and Problematic Advertisements for Medications How GLP-1 Medications Boost Weight

Awareness helps ensure these risks are managed with the right support

NICE guideline NG28 recommends GLP-1 receptor agonists for adults with type 2 diabetes who have a BMI of 35 kg/m or higher (adjusted for ethnicity) and specific psychological or medical problems associated with obesity, or a BMI lower than 35 kg/m where insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities

This means your medication is prepared in a controlled environment designed to maximize the shelf life and safety of the product

I do a lot of different things

The preference for SGLT2i is due to more robust evidence regarding renal outcomes

Anyone promising youll lose 2 lbs